Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study

Chun-Yu Lin¹*, Tseng-Hsi Lin², Chou-Chen Chen¹*, Ming-Cheng Chen¹*, Chou-Pin Chen¹*

¹ Division of Colorectal Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taichung, Taiwan, ² Division of Hematology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan

* Current address: Department of Colorectal Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, ROC

vghtc.crs@gmail.com

Abstract

Background
Regorafenib has been demonstrated as effective in refractory metastatic colorectal cancer. Combination use with chemotherapy has not been reported. We examined the efficacy and safety of adding chemotherapy to Regorafenib for the treatment of metastatic colorectal cancer (mCRC) patients.

Methods
We recruited mCRC patients at our institute who received either regorafenib monotherapy or regorafenib in combination with other chemotherapies. All patients had received chemo and target therapies and presented with disease progression before regorafenib treatment. The primary end point was overall survival.

Findings
Between September 1, 2015 and May 31, 2017, 100 mCRC patients at our institute received regorafenib treatment. 39 patients were excluded due to poor performance, lack of timely treatment, or inadequate clinical data. A total of 34 patients received regorafenib combined with other chemotherapies, and 27 patients received regorafenib alone. Median follow up time was 10.4 and 6.1 months, respectively. The primary end point of median OS was higher in the combination group than in the single use group (20.9m vs 10.3m, p = 0.015). The most frequent adverse events were hand-foot skin reactions (16[47.1%] vs 12[44.4%]), fatigue (6[17.6%] vs 7[25.9%]), gastrointestinal discomfort (7[20.6%] vs 6[22.2%]), neutropenia (4[11.8%] vs 1[3.7%]), diarrhea (4[11.8%] vs 1[3.7%]), and mucositis (5[14.7%] vs 1[3.7%]).
Conclusion
The present study showed the efficacy and side effects of regorafenib combination treatment. Superiority in median OS and median PFS was noted in the combination group. The sampling difference between the study and observation groups effects justifies the comparison. Further clinical evidence of combination therapy efficacy is pending future studies.

Introduction
During the past few decades, the incidence of colorectal cancer has increased worldwide[1]. There were 1,363,000 newly diagnosed cases worldwide, which led to 693,900 deaths in 2012 [2,3]. The colorectal incidence in Taiwan(44.32/100000) is high. There were 15,140 newly diagnosed cases leading to 5,265 deaths in 2013[4]. Approximately 25% of patients with colorectal cancer have metastatic disease with a clinically significant detrimental effect on prognosis[5,6]. With the administration of chemotherapy and target therapy, the median overall survival time of metastatic colorectal cancer (mCRC) has improved from 12 to 33 months (in KRAS wild-type patients)[7,8]. However, the response rate of chemotherapy apparently decreased in the further therapies[9–12]. The identification of a chemotherapy with a higher response rate has attracted increasing attention and is addressed in the present study.

Regorafenib is an orally available, small-molecule multikinase inhibitor that targets signaling pathways implicated in tumor angiogenesis (VEGF receptors 1–3 and TIE2), oncogenesis (KIT, RET, RAF1, and BRAF), and the tumor microenvironment (platelet-derived growth factor receptor and fibroblast growth factor receptor)[12]. Evidence of activity of regorafenib in metastatic colorectal cancer was demonstrated in two international randomized Phase III trials (CORRECT and CONCUR)[13,14]. These trials indicated that regorafenib monotherapy improved overall survival compared with the placebo dose (6.4 months vs 5.0 months, hazard ratio [HR] 0.77, 95% CI 0.64–0.94; p = 0.0052 in CORRECT and 8.8 months vs 6.3 months, [HR] 0.55, 95% CI 0.40–0.77; p = 0.00016 in CONCUR). However, adverse events (AE) of regorafenib were apparent, which were most likely observed as hand-foot skin reaction (HFS), diarrhea, fatigue, and elevated liver function. Adverse events are more frequent observed in Asians, and tolerance was lower[15]. Currently, clinical practice use a dose-escalation protocol at certain institutes[16,17], which may increase drug compliance and with relatively the same effect.

Regorafenib was approved for the treatment of mCRC by the US Food and Drug administration in September 2012[18], and approved in mCRC treatment by the Taiwan National Health Insurance Scheme (NHI) since September 2015[19]. The superiority of combination use of target therapy with chemotherapy was demonstrated in Cetuximab in 2004[20]. The effect of regorafenib combination use remains unknown. We collected mCRC patients from our institute who had received regorafenib combined with chemotherapy and compared these individuals with patients who received only reforafenib to observe differences in the therapeutic effects and side effects between these groups.

Methods
Study design and patients
The present study was a retrospective cohort study; data was collected during September 2015 to May 2017 in a single institute (Fig 1). In Taiwan, chemotherapy for metastatic colorectal cancer.
cancer was paid for by the NHI according to NCCN guidelines[21]. Irinotecan-based chemotherapy (FOLFIRI), and anti-VEGF or anti-EGFR(for k-ras wild type) target therapy were the first line chemotherapies. If the disease progressed, then the patients received a second-line oxaliplatin based(FOLFOX) chemotherapy. In the third-line chemotherapy, anti-EGFR target therapy was used for KRAS wild type, and if anti-VEGF was used in first line, then regorafenib was administered to (Fig 2).

Eligible patients in the present study were pathologically confirmed for colorectal cancer, presented with metastasis and had received target therapy with disease progression within 3 months. The evaluation scale for measurable or non-measurable metastatic disease is according to Response Evaluation Criteria in Solid Tumor(RECIST) version 1.1.23[22]. The patients...
were adults (>18 years of age) with an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate bone-marrow, liver, and renal function at the start of the treatment.

Procedure
We collected data from patients who received regorafenib therapy for metastatic colorectal cancer from September 2015 to May 2017. Patients with an expected life span of fewer than 3 months, brain metastasis, double cancer, regorafenib treatment further than fourth line therapy, or an unclear therapy record were excluded. We verified that the patient records were de-identified and anonymous.

Because of the adverse events of regorafenib, the standard dose was not applicable in every patient. Most physicians applied a dose-escalation protocol, which started with regorafenib at 80 mg per day with possible dosage modifications on each OPD to manage drug concentration and toxic effects. In the study group, there were chemotherapy agents used with regorafenib therapy of either 5-FU based agents, oxaliplatin, irinotecan, FOLFOX, or FOLFIRI. The choice of chemotherapy was determined according to the physicians’ discretion. The dosage of these drugs was determined according to previous study. Tegafur /Uracil: 300 mg/m²/day, capecitabine: 2500 mg/m², oxaliplatin: 85 mg/m² per 2 weeks, irinotecan: 180 mg/m² per 2 weeks, modified FOLFOX6: 2 hour infusion of oxaliplatin (85mg/m²) and folinic acid (100 mg/m²) followed by a 46 hours of continuous infusion of 5-FU (2,400 mg/m²²), FOLFIRI: 90 minutes infusion of irinotecan (180 mg/m²) and folinic acid (100 mg/m²²) followed by a 46 hours of continuous infusion of 5-FU (2,400 mg/m²²). In the control group, regorafenib was used without any chemotherapy. Clinical condition was followed in the outpatient department(OPD) or during hospitalization every 2 weeks, including history-taking, a physical exam, and a laboratory exam. The tumor marker, CEA and CA-199, were assessed every 6–8 weeks, and chest X-ray, abdomen CT, or PET were performed every 10–14 weeks or once if there was a clinical condition that needed to be performed. Survival status was collected by a colorectal cancer case manager in the hospital (Table 1).

Ethics statement
The present study was approved by ethics committees of Taichung Veterans General Hospital in Institutional Review Board(II) 106-B-06 Board Meeting. IRB number: CE17123B. The patients provided informed written consent to have data from their medical records used in the present study. We verified that patient records were de-identified and anonymously analyzed.

Outcome
The primary endpoint was overall survival(OS) (time from regorafenib initiation to mortality by the disease). For these patients, regorafenib might have been the last line treatment. Median overall survival time reflected the disease control rate of the drug. Secondary endpoints were progression-free survival(PFS) (time from regorafenib initiation to clinical evidence including symptoms or radiologic images of disease progression), the proportion of patients who achieved disease control 3 months after treatment, and adverse effects (any grade of symptomatic event, and hematological events). We reported adverse events and laboratory abnormalities using the National Cancer Institute Common Terminology Criteria for Adverse Events category and worst grade.
| Table 1. Patients characteristic in the present study. | Single use (n = 27) | Combine (n = 34) | p value |
|---|---|---|---|
| | n | % | n | % |
| Sex | | | | 1.000 |
| F | 12 | (44.4%) | 14 | (41.2%) |
| M | 15 | (55.6%) | 20 | (58.8%) |
| Age † | 60.0 | (54.0, 73.0) | 63.0 | (58.8, 73.3) | 0.292 |
| ECOG | | | | 0.162 |
| 0 | 2 | (7.4%) | 8 | (23.5%) |
| 1 | 25 | (92.6%) | 26 | (76.5%) |
| Drug | | | | |
| XeLIRI or FOLFIRI | 0 | (0.0%) | 5 | (14.7%) |
| Ufur or Xeloda | 0 | (0.0%) | 7 | (20.6%) |
| FOLFOX | 0 | (0.0%) | 1 | (2.9%) |
| Irino | 0 | (0.0%) | 19 | (55.9%) |
| Oxa | 0 | (0.0%) | 2 | (5.9%) |
| Initial dosage (mg) | | | | 0.429 |
| 80 | 24 | (88.9%) | 29 | (85.3%) |
| 120 | 0 | (0.0%) | 2 | (5.9%) |
| 160 | 3 | (11.1%) | 3 | (8.8%) |
| Tumor site | | | | 0.039* |
| Cecum | 3 | (11.1%) | 0 | (0.0%) |
| Ascending colon | 1 | (3.7%) | 3 | (8.8%) |
| Transverse colon | 1 | (3.7%) | 0 | (0.0%) |
| Descending colon | 0 | (0.0%) | 5 | (14.7%) |
| Sigmoid colon | 5 | (18.5%) | 11 | (32.4%) |
| Rectum | 17 | (63.0%) | 15 | (44.1%) |
| Side | | | | 0.447 |
| Right | 5 | (18.5%) | 3 | (8.8%) |
| Left | 22 | (81.5%) | 31 | (91.2%) |
| Ras mutation | | | | 1.000 |
| Wild type | 12 | (44.4%) | 15 | (44.1%) |
| Mutant type | 15 | (55.6%) | 19 | (55.9%) |
| Time when regorafenib was used | | | | 0.940 |
| 2nd line | 8 | (29.6%) | 10 | (29.4%) |
| 3rd line | 14 | (51.9%) | 18 | (52.9%) |
| 4th line | 5 | (18.5%) | 6 | (17.6%) |
| Had received adjuvant therapy in stage 3 | | | | |
| FOLFOX | 8 | (29.6%) | 11 | (32.4%) | 1.000 |
| Target therapy before regorafenib | | | | 0.153 |
| Bevacizumab | 17 | (63.0%) | 20 | (58.8%) |
| Cetuximab | 6 | (22.2%) | 3 | (8.8%) |
| Bevacizumab+ Cetuximab | 4 | (14.8%) | 11 | (32.4%) |
| Chemotherapy before regorafenib | | | | 1.000 |
| FOLFIRI /XeLIRI | 12 | (44.4%) | 16 | (47.1%) |
| FOLFOX | 0 | (0.0%) | 0 | (0.0%) |
| FOLFIRI and FOLFOX | 15 | (55.6%) | 18 | (52.9%) |

Chi-square test. †Mann-Whitney U test, Median (IQR)
*p<0.05
**p<0.01

https://doi.org/10.1371/journal.pone.0190497.t001
Statistical analysis
The present study compared regorafenib combination therapy and monotherapy. Analyses were performed using the Statistical Package for the Social Science (IBM SPSS version 22.0; International Business Machines Corp, New York, USA). We compared the overall survival and progression-free survival using a stratified log-rank test and calculated HRs (with 95% CIs) using the Cox model, adjusting for baseline stratification factors. We calculated Kaplan-Meier survival estimates for each treatment group. We provide descriptive statistics and 95% CIs for overall survival and progression-free survival analyses.

The study was designed to confirm our hypothesis that combination therapy would extend median PFS and OS. The PFS in the study group was expected to be 3.5 months compared with 1.7 month based on the results of a previous study. A two-sided log rank test with an overall sample size of 68 subjects (34 in the control group and 34 in the treatment group) achieves 80.4% power at a 0.050% significance level to detect a hazard ratio of 0.4857.

Role of the funding source
The present study received little funding. The present study was a retrospective, double arm cohort study for the mCRC patients treated in single institute. Collection of data, medical documents, laboratory data, and statistical analyses were conducted by the authors and the Biostatistics Task Force of Taichung Veterans General Hospital, who were responsible for the study results.

Results
The baseline characteristics of both groups were not significantly different. In the combination treatment group, regorafenib was combined with FOLFIRI in 4 (11.8%) patients, Ufur/Xeloda in 7 (20.6%) patients, FOLFOX in 2 (5.8%) patients, Irino in 19 (55.9%) patients, and oxaliplatin in 2 (5.8%) patients. There were 2 patients who received a combination of regorafenib with oxaliplatin, and these individuals had undergone FOLFOX for second line therapy without discomfort. Oxaliplatin was added to regorafenib. By dose-escalating protocol, initial dosage was 80 mg per day in 29 (85.3%) patients in the combination group and 24 (88.9%) patients in the single use group. A total of 160 mg per day in 3 (8.8%) patients in the combination group and 3 (11.1%) patients in the single use group. Regorafenib was used as a second line treatment after metastasis was confirmed in 10 (30.3%) patients in the combination group and 8 (29.6%) patients in the single use group. In third line treatment in 18 (54.5%) patients in the combination group and 14 (51.9%) patients in the single use group. Fourth line treatment: 5 (15.2%) vs 5 (18.5%). Before regorafenib, 20 (58.8%) patients had received Avastin, 3 (8.8%) patients had received cetuximab, and 11 (32.4%) patients received both of treatments in the combination group. Avastin: 17 (63.3%); cetuximab: 6 (22.2%); Both: 4 (14.8%) in the single use group.

Median follow up time was 10.4 months in the combination group and 6.1 months in the single use group. After regorafenib treatment with a dose-escalation protocol, there were 2 (6.9%) patients with increased dose in the combined use group and 2 (8.3%) patients in the single use group. A total of 4 (13.8%) patients showed a decreased dose in the combined use group and 3 (12.5%) patients in the single use group. The final regorafenib daily dosages were 40 mg in 4/34 (11.8%), 80 mg in 27/34 (79.4%), 120 mg 1/34 (2.9%), 160 mg in 2/34 (5.9%) in combined use group and 3/27 (11.1%), 19/27 (70.4%), 2/27 (7.4%), and 3/27 (11.1%) in the single use group. The dosage of regorafenib was not different between combination use and single use. Median therapeutic duration was 4.5 months (2.8–6.8) in the combination group and 2.9 months (2.0–4.0) in the single use group ($p = 0.037$). Disease control rate after three months treatment was 47.1% (16/34) in the combination group and 11.1% (3/27) in the single use.
Ending of regorafenib treatment was due to disease progression: 70.6% (24/34) in the combination group and 70.4% (19/27) in the single use group; or adverse effects: 23.5% (8/34) vs 25.9% (7/27). The adverse effects of combination use did not increase the risk of treatment failure (Table 2).

The primary end point of overall survival (OS). The OS curve is shown in Fig 3. Median OS was 20.9 (10.1–31.7) months in the combination group and 10.3 (8.3–12.3) months in the single use group ($p = 0.015$). A second end point of progression-free survival (PFS) (Fig 4) was 3.7 (2.2–5.2) months in the combination group and 2.5 (1.7–3.4) months in the single use group ($p = 0.009$). A total of 58.3% patients remained alive at the 1-year follow up in the combination group and 26.8% patients in the single use group. The combination group had longer overall survival and progression-free survival.

Overall, there were 27 patients (79.4%) suffered from any grade of adverse effect in combination group and 18 patients (66.6%) in single use group (Table 3). Most frequently seem were hand food skin reaction (HFSR), gastrointestinal discomfort, and fatigue. Adverse effects predominantly noted in combination group were mucositis (14.7% vs 3.7%), diarrhea (11.8% vs 3.7%), neutropenia (11.8% vs 3.7%), and thrombocytopenia (2.9% vs 0%).

### Discussion

The optimal dosage for regorafenib is not known. The suggested dosage was 160mg per day for 3 weeks and rest for 1 week according to the best drug concentration recommended in a previous study [23]. However, drug compliance was not good and most patients needed adjustments. The minimal daily dose of regorafenib allowed was 80mg [24]. This dose was selected as no data on antitumor activity was generated with lower concentrations in a previous study [25].

---

**Table 2. Results of the present study.**

|                    | Single use (n = 27) | Combine (n = 34) | $p$ value |
|--------------------|---------------------|------------------|-----------|
| **Final dosage (mg)** |                     |                  |           |
| 40                 | 3 (11.1%)           | 4 (11.8%)        | 0.734     |
| 80                 | 19 (70.4%)          | 27 (79.4%)       |           |
| 120                | 2 (7.4%)            | 1 (2.9%)         |           |
| 160                | 3 (11.1%)           | 2 (5.9%)         |           |
| **Response after 3 months treatment** |                   |                  | 0.006**   |
| Progress Disease (PD) | 24 (88.9%)          | 18 (52.9%)       |           |
| Stable disease (SD)  | 3 (11.1%)           | 16 (47.1%)       |           |
| **Reasons to stop regorafenib** |                   |                  | 0.914     |
| Progress Disease (PD) | 19 (70.4%)          | 24 (70.6%)       |           |
| Adverse events (AE)  | 7 (25.9%)           | 8 (23.5%)        |           |
| Regorafenib was ongoing | 1 (3.7%)         | 2 (5.9%)         |           |
| **Duration of regorafenib** |           |                  | 0.037*    |
| 2.9 (2.0, 4.0)       | 4.5 (2.8, 6.8)      |               |
| **Follow-up time†**  |                     |                  | 0.058     |
| OS                  | 6.1 (5.3, 10.5)     | 10.4 (5.7, 13.1) |           |
| PFS                 | 2.5 (1.6, 3.6)      | 4.0 (2.5, 5.9)   | 0.014*    |

Chi-square test.
†Mann-Whitney U test, Median (IQR)
*p<0.05
**p<0.01

https://doi.org/10.1371/journal.pone.0190497.t002

---
Thus, certain physicians started regorafenib at 80 mg daily for the first week, escalated the dosage to 120 mg daily for the second week if no significant side effect was observed, and subsequently escalated the dosage again to 160 mg daily, for the third week, then scheduled a break for the fourth week[16]. At our institute, most physicians initiated regorafenib at the 80-mg daily dose. Dosage up-regulation was determined at the physicians’ discretion. Most patients remained at 80 mg daily at our institute.

Another real-life regorafenib experience was shared by Ka-On Lam et al., who recruited 45 patients in three institutes in Hong Kong[26]. A total of 25 patients were treated at a lower dose, and 20 patients were started at a full dose. Median overall survival time was not inferior in low dose regorafenib (51.3 weeks vs 27.4 weeks, p = 0.449) nor was median progression-free survival time (18.7 weeks vs 13.4 weeks, p = 0.458). The adverse effects of a full dose of regorafenib made this dosage not practical in every case. Hence, low dose initiation was relatively feasible in clinical practice and might confer the same effect.

There was a Phase IB study by B. Schiltheis that analyzed the combination of regorafenib with FOLFOX or FOLFIRI in first or second line chemotherapy[27]. The study recruited 45 patients using combination therapy with regorafenib 160 mg daily and standard FOLFOX or FOLFIRI. Median PFS was 126 days. Similar PFS between first line and second therapy either combined with FOLFOX or FOLFIRI was noted. Adverse effects were acceptable. However, combination use was not suggested due to more adverse effects and non-superior outcomes to chemotherapy alone.
Fig 4. Progression-free survival Kaplan-Meier analysis of combination and single use group.

Table 3. Adverse effects occurring after treatment.

|                          | Single use (n = 27) | Combine (n = 34) | p value |
|--------------------------|---------------------|------------------|---------|
|                          | n                   | %                | n       | %      |         |
| Any events               | 18                  | (66.6%)          | 27      | (79.4%)| 0.406   |
| HFSR                     | 12                  | (44.4%)          | 16      | (47.1%)| 1.000   |
| headache                 | 1                   | (3.7%)           | 1       | (2.9%) | 1.000   |
| mucositis                | 1                   | (3.7%)           | 5       | (14.7%)| 0.317   |
| N/V                      | 6                   | (22.2%)          | 7       | (20.6%)| 1.000   |
| Diarrhea                 | 1                   | (3.7%)           | 4       | (11.8%)| 0.371   |
| Hypertension             | 1                   | (3.7%)           | 0       | (0.0%) | 0.443   |
| Fatigue                  | 7                   | (25.9%)          | 6       | (17.6%)| 0.639   |
| Discomfort               | 2                   | (7.4%)           | 0       | (0.0%) | 0.374   |
| Liver function elevation | 2                   | (7.4%)           | 3       | (8.8%) | 1.000   |
| Thrombocytopenia         | 0                   | (0.0%)           | 2       | (5.9%) | 0.498   |
| Hair loss                | 0                   | (0.0%)           | 2       | (5.9%) | 0.498   |
| Neutropenia              | 1                   | (3.7%)           | 4       | (11.8%)| 0.371   |

Chi-square test. *p<0.05, **p<0.01
Regorafenib combination use was reported by Wang et al.[28]. Regorafenib combined with FOLFIRI was used in a metastatic colorectal cancer patient in fourth line therapy after FOLFIRI, FOLFOX, cetuximab, and bevacizumab were used. The dosage of regorafenib was 160mg daily and FOLFIRI was initiated from 180 mg/m$^2$ for irinotecan with subsequent up regulation to 290 mg/m$^2$. A partial response was achieved and PFS was longer than 6 months. Currently, there are no cases concerning regorafenib combination use in third line chemotherapy. The optimal regimens for regorafenib combination therapy are also not known. We used sub group different combination therapy and observed overall survival time. The results are shown in Table 4.

The optimal dosage for combination therapy was not defined. Physicians administered dosages according to a previous study. There were no severe adverse effects noted in the present study after these regimens were combined with regorafenib. The outcome of regorafenib combination use was superior to that of single use.

**Conclusion**

Regorafenib combination use with conventional chemotherapy, either single regimen 5-FU, irinotecan, oxaliplatin, or combination regimen FOLFIRI/ FOLFOX, brought superior survival benefit than single use. Side effects were tolerable without decreasing drug compliance. Optimal regimen and dosage of the combination treatment are pending future studies.

**Supporting information**

S1 File. The file contains the raw data underlying the present study. (XLSX)

**Acknowledgments**

The present study was supported in part by the study projects of Taichung Veterans General Hospital- CE17123B which was not support from other financial group. The authors would like to thank the Department of Colorectal Surgery and Cancer Registry of Taichung Veterans General Hospital for assistance with data collection and the Biostatistics Task Force of Tai-chung Veterans General Hospital for data analysis.

**Author Contributions**

**Conceptualization:** Tseng-Hsi Lin, Chou-Pin Chen.

**Data curation:** Chun-Yu Lin.

**Investigation:** Chun-Yu Lin, Chou-Chen Chen.

**Methodology:** Tseng-Hsi Lin, Chou-Chen Chen.
Project administration: Chou-Chen Chen, Chou-Pin Chen.

Software: Chou-Chen Chen.

Supervision: Tseng-Hsi Lin, Chou-Pin Chen.

Writing – original draft: Chun-Yu Lin, Chou-Chen Chen.

Writing – review & editing: Tseng-Hsi Lin, Ming-Cheng Chen, Chou-Pin Chen.

References

1. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009; 18: 1688–94. https://doi.org/10.1158/1055-9965.EPI-09-0090 PMID: 19505900

2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. http:// onlinelibrary.wiley.com/doi/10.3322/caac.21262/full (accessed Feb 12, 2017)

3. Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, et al. Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus. Clin Colorectal Cancer 2014; 13: 145–55. https://doi.org/10.1016/j.clcc.2014.06.004 PMID: 25209093

4. Taiwan Ministry of Health and welfare: malignant tumor: Incidence in Taiwan in 2012. http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=5477, (accessed Feb 1, 2017)

5. Lemmens V, van Steenbergen L, Janssens-Heijnen M, Martijn H, Rutten H, Coebergh JW. Trends in colorectal cancer in the south of the Netherlands 1975–2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 2010; 49: 784–96. https://doi.org/10.3109/02841861003733713 PMID: 20429731

6. Van Cutsem E, Borras JM, Castells A, Ciardiello F, Duceux M, Haq A, et al. Improving outcomes in colorectal cancer: where do we go from here? Eur J Cancer 2013; 49: 2476–85. https://doi.org/10.1016/j.ejca.2013.03.026 PMID: 23642327

7. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Markson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408–1417 https://doi.org/10.1056/NEJMoa0805019 PMID: 19339720

8. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology 2016; 27: 1386–1422. https://doi.org/10.1093/annonc/mdw235 PMID: 27380959

9. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al: Bevacizumab in combination with Oxaliplatin-Based chemotherapy as first-Line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008; 26: 2013–2019 https://doi.org/10.1200/JCO.2007.14.9930 PMID: 18421054

10. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFIRI) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. Journal of Clinical Oncology 2007; 25: 1539–1544 https://doi.org/10.1200/JCO.2006.09.6305 PMID: 17442997

11. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England Journal of Medicine 2008; 359: 1757–1765 https://doi.org/10.1056/NEJMoa0804385 PMID: 18946061

12. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncopgenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245–55. https://doi.org/10.1002/ijc.25864 PMID: 21170960

13. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT): an international, multicentre, randomized, placebo controlled, phase 3 trial. Lancet 2013; 381: 303–12. https://doi.org/10.1016/S0140-6736(12)61900-X PMID: 23177514

14. Li J, Qin S, Xu R, Yau TCC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONFUR): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619–29. https://doi.org/10.1016/S1470-2045(15)01056-7 PMID: 25981918

15. Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, et al. Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese
16. Grothey A. Optimal use of Regorafenib: Dosing strategies and patient selection. Clinical advances in Hematology & Oncology Volume 14, Issue 3, supplement 3, March 2016

17. Grothey A. Regorafenib in Metastatic colorectal cancer: Optimal dosing and patient selection recommendations. Clinical advances in Hematology & Oncology Volumn 13, Issue 8, supplement 8, August 2015

18. US Food and Drug Administration (2012) FDA approves regorafenib(Stivarga) for metastatic colorectal cancer. Oncology (WillistonPark) 26:896

19. National Health Insurance Administration, ministry of health and welfare payment for antineoplastic drugs 9.51. regorafenib. http://www.nhi.gov.tw/Resource/bulletin/6449_1050035949-2.pdf (accessed Feb 12, 2017).

20. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. The New England Journal of Medicine 2004; 351: 337–45 https://doi.org/10.1056/NEJMoa033025 PMID: 15269313

21. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer. Version 2.2016. https://www.tri-kobe.org/nccn/guideline/colorectal/english/colon.pdf (accessed Feb 12, 2017).

22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1). Eur J Cancer 2009; 45: 228–47 https://doi.org/10.1016/j.ejca.2008.10.026 PMID: 19097774

23. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, et al. Regorafenib (BAY 73–4506) in advanced colorectal cancer:a phase I study. British Journal of Cancer 2012; 106, 1722–1727 https://doi.org/10.1038/bjc.2012.153 PMID: 22568966

24. Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD. Optimizing Treatment OutcomesWith Regorafenib: PersonalizedDosing and Other Strategies to Support Patient Care. The oncologist; 2014; 19:1–12 https://doi.org/10.1634/theoncologist.2013-0392

25. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, et al. A Phase I Dose–Escalation Study of Regorafenib(BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors. Clin Cancer Res; 18(9) May 1, 2012; 2659–2667

26. Lam KO, Lee KC, Chiu J, Lee VH, Leung R, Choy TS, et al. The real-world use of regorafenib for metastaticcolorectal cancer: multicentre analysis of treatmentpattern and outcomes in Hong Kong. Postgrad Med J 2016; 0:1–6

27. Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer:results of a multicenter, phase Ib study. Annals of Oncology 24: 1560–1567, 2013 https://doi.org/10.1093/annonc/mdt056 PMID: 23493136

28. Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ, Wang JY. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. OncoTargets and Therapy; 2014: 7 2143–2146 https://doi.org/10.2147/OTT.S69774 PMID: 25473295